French biotech company TxCell has appointed François Meyer as its executive chairman as it completes a strategic realignment around its CAR-Treg research programmes.
In his new role Meyer will head up Valbonne-based TxCell’s newly-formed research group, which is made up of Cell Engineering, Pharmacology and Process Development units and comprises of 31 employees.
Meyer brings 35 years of industry experience to his new position, accrued from firms such as Rhone Poulenc Rorer and Aventis Pharma (both now part of Sanofi), where he served as head of research.
As part of the changes Dr Miguel Forte, executive vice president and chief operating officer, will be leaving the company.
Stéphane Boissel, CEO of TxCell, said: “TxCell has now completed its strategic and organizational transformation. I would like to thank all stakeholders, notably Miguel Forte, for their contribution to this rapid, profound turnaround.
“We can now look to the future with great expectations and with one major objective in mind: for TxCell to be the first organization ever to put a CAR-Treg product in clinical development, with the aim of achieving this by 2018.”